Del 64 - Annual Reports in Medicinal Chemistry

Machine Learning in Drug Development: Part 1

Nyhet

Inbunden, Engelska, 2025

Av Katherine Seley-Radtke

2 429 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Machine Learning in Drug Development: Part One, Volume 64 in the Annual Reports on Medicinal Chemistry series, highlights new advances in the field. Chapters in this release include Artificial Intelligence in Small Molecule and Nucleic Acid Research: A Review, AI-aided Drug Development for Protein Degraders: Design, Lead Identification, and Optimization, AI-aided Drug Development for Protein Degraders: Biology Validation, Disease-association, Drug Repurposing, Transforming Modern Drug Discovery with Machine Learning, Artificial Intelligence in the Development of Antiviral Drugs: Progress and Applications, Artificial Intelligence for Drug Target Identification, and Machine Learning in Proteomic Biomarker Discovery.

Provides the authority and expertise of leading contributors from an international board of authors
Presents the latest release in Annual Reports on Medicinal Chemistry series
Updated release includes the latest information in the field

Produktinformation

Utgivningsdatum2025-10-24
Mått152 x 229 x undefined mm
Vikt450 g
FormatInbunden
SpråkEngelska
SerieAnnual Reports in Medicinal Chemistry
Antal sidor176
FörlagElsevier Science
MedarbetareFeng,Joy
ISBN9780443413650

Tillhör följande kategorier

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach tonucleoside, nucleotide and heterocyclic drug discovery and development with therapeuticemphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currentlyused drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served asthe Program Director for UMBC’s Chemistry-Biology Interface graduate training programfunded by NIH since 2007. This program promotes hands on cross disciplinary research foralmost 50 PhD students from four departments at UMBC and UMB. She is currently theImmediate Past President and Secretary-Elect for the International Society of Nucleosides,Nucleotides and Nucleic Acids and a Board member of the International Society for AntiviralResearch. Prof. Seley-Radtke also serves as a standing member for several NIH study sectionsand is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,Molecules – Chemical Biology, and Current Protocols in Chemical Biology. Joy is an Associate Professor of Pediatrics at Emory University with a 25-year experience in the pharmaceutical industry. She received her B.S. from Peking University School of Pharmaceutical Sciences, her Ph.D. in Medicinal Chemistry from Dr. Raymond Bergeron’s lab at the University of Florida School of Pharmacy, and postdoctoral training in enzymology in Dr. Karen Anderson’s lab at Yale University School of Medicine. Joy’s research focuses on drug mechanisms of action, drug combinations, drug resistance, drug metabolism, off-target effects, and toxicity. Joy contributed to the approval of three marketed drugs: Emtricitabine (FTC) for HIV, Sofosbuvir for HCV, and is one of the inventors of Remdesivir, the first FDA-approved direct antiviral for treating COVID-19, and Obeldesivir (GS-5245), currently in clinical trials for the treatment of RSV infection.

1. Artificial Intelligence in Small Molecule and Nucleic Acid Research: A Review2. AI-aided Drug Development for Protein Degraders: Design, Lead Identification, and Optimization3. AI-aided Drug Development for Protein Degraders: Biology Validation, Disease-association, Drug Repurposing4. Transforming Modern Drug Discovery with Machine Learning5. Artificial Intelligence in the Development of Antiviral Drugs: Progress and Applications6. Artificial Intelligence for Drug Target Identification7. Machine Learning in Proteomic Biomarker Discovery